Abstract
Pharmaceutical development costs represent a large and escalating part of sales and profits. In many companies, managers have found that the traditional cost accounting methods are not very useful for improving the efficiency and effectiveness of development activities. To complement traditional systems, we propose activity-based costing (ABC) as a powerful tool for helping both to control costs and to provide ideas for reducing lead times. This article reviews the principles of activity-based costing and illustrates the application of these methods to data management processes in clinical development. Drug Dev. Res. 43:164–173, 1998. © 1998 Wiley-Liss, Inc.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
